Back to the Top
Dear All,
I have got a pivotal parallel study (two treatment) for statistical
analysis using SAS software. Since I have not dealt with this type of
design in SAS soft ware, could anybody suggest me how to proceed with
the statistical analysis.
Or else please tell me is it ANOVA one-way procedure used for a
parallel study (two treatment) in SAS soft ware,In ANOVA one way
could anybody tell me which test to be applied (Bartlette,
Duncan.....and so on).
And also please tell me what factors/effects (treatment or subject or
both) should be taken for statistical analysis in ANOVA one-way
procedure
Please tell me any guideline or books or any websites which gives a
clear picture regarding the statistical analysis of a parallel study.
Note: Kindly treat this as high priority and reply me at the earliest
as it is very urgent
--
Regards,
MGR
Statistical Analyst
Back to the Top
You have got at least 2 treatments, multiple doses? multiple time
points, repeated measures. it would seem that you would be looking
at the differences of equivalence of the two drugs, each dose, each
time point so it should be drugXdoseXtime, that would be 3 way-main
effects drug then interactions drugXdose, drugXtime and doseXtime
with DRUGXDoseXtime, unless I am missing something.
Back to the Top
Hi,
Well the design path analysis would be oneway Anova and a bartlett's
test
Good luck
Back to the Top
The following message was posted to: PharmPK
Dear MGR
To me, for two treatments in parallel design, parameteric (unpaired t
test) or nonparameteric (MannWhitney test).
Nadeem
Back to the Top
The objective of this analysis is not clear but assuming that it is a
bioequivalence type study and you have parametric data, then you can
analyze the data using PROC GLM. For a parallel design, you only need
to consider treatment as a factor in the model. If applicable, then
you might also want to log transform the parameters accordingly. And
since there are only two treatments, you don't need Duncan's test for
multiple comparisons. Bartlett's test is for testing non-normality of
the data.
You can also consult the FDA guidelines for guidance on the
statistical analysis.
Nav Coelho
Biostatistician, Biovail Contract Research
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)